During her panel for FDAnews, Nancy Myers highlighted impending challenges looming over FDA’s commissioner hopeful, Robert Califf. If confirmed, Califf would enter the FDA at a time crucial to rebuilding public trust in the Agency and drive COVID-related learnings. She noted that with the increasing politicalization of the FDA comes additional scrutiny concerning the drug-approval process, making “maintaining the agency’s gold standard perception” more difficult than ever. Robust federal funding will be needed in order to meet Califf’s initiatives concerning increased use of real-world data and increasing the size of clinical trials. To read more about the upcoming challenges Califf will face in 2022, click this LINK.
